Literature DB >> 3815299

Prognostic index for malignant melanoma.

A W Kopf, D F Gross, G S Rogers, D S Rigel, L J Hellman, M Levenstein, B Welkovich, R J Friedman, D F Roses, R S Bart.   

Abstract

This report verifies the ability of a Prognostic Index (PI) to accurately predict 5-year survival rates for 879 Stage I cutaneous malignant melanoma (MM) patients seen at New York University Medical Center. The PI used in this study was first reported from Munich, West Germany, and is calculated from standard histologic sections by multiplying the MM thickness in millimeters (Breslow method) by the number of MM mitoses per square millimeter. A PI value of less than 19 versus greater than or equal to 19 was found to be a significant and independent prognostic variable for Stage I MM when compared with seven other predictive variables (including Breslow thickness). These PI intervals identified a subgroup of patients with MM of intermediate thicknesses (1.50-3.49 mm) whose significantly worse survival would not have been anticipated if prognosis were determined by Breslow thickness alone. For example, patients with MM 1.50 to 2.49 mm thick have a 5-year survival rate of 84.1% determined by Breslow thickness alone; however, among these patients exists a subgroup with PI greater than or equal to 19 whose survival rate is only 57.6%. This study verifies the additive usefulness of the PI in predicting survival rates of patients with Stage I cutaneous MM.

Entities:  

Mesh:

Year:  1987        PMID: 3815299     DOI: 10.1002/1097-0142(19870315)59:6<1236::aid-cncr2820590634>3.0.co;2-i

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  7 in total

1.  Tumor cell growth fractions in human malignant melanomas and the correlation to histopathologic tumor grading.

Authors:  P Kaudewitz; O Braun-Falco; M Ernst; M Landthaler; W Stolz; J Gerdes
Journal:  Am J Pathol       Date:  1989-05       Impact factor: 4.307

2.  Fractal characterisation of boundary irregularity in skin pigmented lesions.

Authors:  A Piantanelli; P Maponi; L Scalise; S Serresi; A Cialabrini; A Basso
Journal:  Med Biol Eng Comput       Date:  2005-07       Impact factor: 2.602

3.  Experience of a public education programme on early detection of cutaneous malignant melanoma.

Authors:  V R Doherty; R M MacKie
Journal:  BMJ       Date:  1988-08-06

4.  Clinicopathological characteristics at primary melanoma diagnosis as risk factors for brain metastasis.

Authors:  Meng Qian; Michelle W Ma; Nathaniel H Fleming; Daniel J Lackaye; Eva Hernando; Iman Osman; Yongzhao Shao
Journal:  Melanoma Res       Date:  2013-12       Impact factor: 3.599

5.  Challenging the current paradigm of melanoma progression: brain metastasis as isolated first visceral site.

Authors:  Michelle W Ma; Meng Qian; Daniel J Lackaye; Russell S Berman; Richard L Shapiro; Anna C Pavlick; John G Golfinos; Erik C Parker; Farbod Darvishian; Eva Hernando; Yongzhao Shao; Iman Osman
Journal:  Neuro Oncol       Date:  2012-05-03       Impact factor: 12.300

6.  Proliferative activity of primary cutaneous melanocytic tumours.

Authors:  T Kuwata; M Kitagawa; T Kasuga
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  The relationship between mitotic rate and depth of invasion in biopsies of malignant melanoma.

Authors:  Hamid Reza Ghasemi Basir; Pedram Alirezaei; Sara Ahovan; Abbas Moradi
Journal:  Clin Cosmet Investig Dermatol       Date:  2018-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.